Aicuris Gmbh + Co. Kg.

Other

Otago Innovation Limited

Andrew Allan Mercer

Stephen Bruce Fleming

Olaf Weber

Hans-Dieter Volk

Angela Siegling

Tobias Schlapp

Sonja Maria Tennagels

Lyn Marie Wise

Steven Alan Stacker

Sonja Maria Friederichs

Loreen J Savory

Sonja-Maria Friederichs

The invention relates to polynucleotides coding for the PPVO viral genome, to fragments of the polynucleotides coding for the PPVO genome and to polynucleotides coding for individual open reading frames (ORFs) of the PPVO viral genome. The invention also relates to recombinant proteins expressed from the above mentioned polynucleotides and to fragments of said recombinant proteins, and to the use of said recombinant proteins or fragments for the preparation of pharmaceutical compositions.

Recombinant proteins of parapdxvirus ovis and pharmaceutical compositions therefrom

Viral VEGF and viral anti-inflammatory cytokine compositions, methods of treatment using them, and kits containing them for use in the promotion and/or improvement of wound healing and/or tissue repair, and for anti-scarring, anti-inflammatory, anti-fibrosis and anti-adhesion indications.

Combination treatments and compositions for wound healing comprising viral VEGF

[object Object]

Recombinant proteins of parapoxvirus ovis and pharmaceutical compositions therefrom

The invention is based on the discovery that a viral VEGF-like protein from the orf virus strain NZ2 and from the orf virus strain NZ10 is capable of binding to the extracellular domain of the VEGF receptor-2 to form bioactive complexes which mediate useful cellular responses and/or antagonize undesired biological activities. Disclosed are methods which stimulate or inhibit these biological activities, methods for therapeutic applications and antagonists of ORFV2-VEGF and/or NZ10.

Vascular endothelial growth factor-like protein from orf viruses binds and activates mammalian VEGF receptor-2, and uses thereof

Growing community of inventors

Dunedin, New Zealand

Andrew Allan Mercer